BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Zhang S, Wang YM, Sun CD, Lu Y, Wu LQ. Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma. World J Gastroenterol 2008; 14(23): 3750-3753 [PMID: 18595144 DOI: 10.3748/wjg.14.3750]
URL: https://www.wjgnet.com/1007-9327/full/v14/i23/3750.htm
(0) (0) (7178) (53)
Number Citing Articles
1
Hu Qiong-ying, Kai-zheng Wang, Yin-huan Ding, Lv-fang Zheng, Shuang-hua Liang, Zheng-ming Lei, Wen-guang Fu, Li Yan. Application of SELDI-TOF-MS Coupled With an Artificial Neural Network Model to the Diagnosis of Pancreatic Cancer. Laboratory Medicine 2010; 41(11) doi: 10.1309/LMH6TUOMQKX6V2DN
2
Marco La Torre, Giuseppe Nigri, Annalisa lo Conte, Federica Mazzuca, Simone Maria Tierno, Adelona Salaj, Paolo Marchetti, Vincenzo Ziparo, Giovanni Ramacciato. Is a Preoperative Assessment of the Early Recurrence of Pancreatic Cancer Possible after Complete Surgical Resection?. Gut and Liver 2014; 8(1) doi: 10.5009/gnl.2014.8.1.102
3
Hai-Xing Jiang, Wei Luo, Wen Chen, Shan-Yu Qin, Si-Biao Su. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World Journal of Gastroenterology 2015; 21(14): 4323-4333 doi: 10.3748/wjg.v21.i14.4323
4
Nicolas Santucci, Olivier Facy, Pablo Ortega-Deballon, Jean-Baptiste Lequeu, Paul Rat, Patrick Rat. CA 19–9 predicts resectability of pancreatic cancer even in jaundiced patients. Pancreatology 2018; 18(6) doi: 10.1016/j.pan.2018.07.001
5
Erin G. Brown, Robert J. Canter, Richard J. Bold. Preoperative CA 19‐9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma. Journal of Surgical Oncology 2015; 111(3) doi: 10.1002/jso.23812
6
Antonella De Rosa, Iain C. Cameron, Dhanwant Gomez. Indications for staging laparoscopy in pancreatic cancer. HPB 2016; 18(1) doi: 10.1016/j.hpb.2015.10.004
7
Shuli Yang, Ruixue Ma, Jing Wu. The diagnostic value of combining preoperative serum CA19-9, ALBI score, and 18F-FDG PET/CT imaging in preoperative resectability of pancreatic cancer. Nuclear Medicine Communications 2024; 45(12) doi: 10.1097/MNM.0000000000001910
8
Young Choon Kim, Hong Joo Kim, Jung Ho Park, Dong Il Park, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Jun Ho Shin. Can preoperative CA19‐9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?. Journal of Gastroenterology and Hepatology 2009; 24(12) doi: 10.1111/j.1440-1746.2009.05935.x
9
Holger Husi, Richard J. E. Skipworth, Andrew Cronshaw, Nathan A. Stephens, Henning Wackerhage, Carolyn Greig, Kenneth C. H. Fearon, James A. Ross. Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn‐5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer. PROTEOMICS – Clinical Applications 2015; 9(5-6) doi: 10.1002/prca.201400111
10
Shinji Itoh, Eiji Tsujita, Kengo Fukuzawa, Keishi Sugimachi, Tomohiri Iguchi, Mizuki Ninomiya, Takashi Maeda, Kiyashi Kajiyama, Eisuke Adachi, Hideaki Uchiyama, Tohru Utsunomiya, Yasuharu Ikeda, Soichirou Maekawa, Takeo Toshima, Noboru Harada, Tomoharu Yoshizumi, Masaki Mori. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study. Pancreatology 2021; 21(7) doi: 10.1016/j.pan.2021.08.003
11
Mitsuro Kanda, Tsutomu Fujii, Hideki Takami, Masaya Suenaga, Yoshikuni Inokawa, Suguru Yamada, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Shuji Nomoto, Yasuhiro Kodera. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surgery Today 2014; 44(9) doi: 10.1007/s00595-013-0752-9
12
Salvatore Scarà, Patrizia Bottoni, Roberto Scatena. Advances in Cancer Biomarkers. Advances in Experimental Medicine and Biology 2015; 867 doi: 10.1007/978-94-017-7215-0_15
13
Kimberly M. Brown. Multidisciplinary Approach to Tumors of the Pancreas and Biliary Tree. Surgical Clinics of North America 2009; 89(1) doi: 10.1016/j.suc.2008.09.022
14
He Cheng, Guopei Luo, Kaizhou Jin, Zhiwen Xiao, Yunzhen Qian, Yitao Gong, Xianjun Yu, Chen Liu. Predictive Values of Preoperative Markers for Resectable Pancreatic Body and Tail Cancer Determined by MDCT to Detect Occult Metastases. World Journal of Surgery 2021; 45(7) doi: 10.1007/s00268-021-06047-x
15
Márton Benke, Nelli Farkas, Péter Hegyi, Benedek Tinusz, Patrícia Sarlós, Bálint Erőss, Kata Szemes, Nóra Vörhendi, Zsolt Szakács, Ákos Szücs. Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis. Pathology and Oncology Research 2022; 28 doi: 10.3389/pore.2022.1610266
16
Umashankar K. Ballehaninna, Ronald S. Chamberlain. Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive Review. Indian Journal of Surgical Oncology 2011; 2(2) doi: 10.1007/s13193-011-0042-1
17
Ying Li, Xiaojuan Yang, Zhanzhan Zhang, Xiaoning Kang, Shanglong Liu. Accuracy of preoperative serum CA19-9 levels in predicting the resectability of patients with pancreatic adenocarcinoma. Oncology and Translational Medicine 2018; 4(1) doi: 10.1007/s10330-018-0249-9
18
Su Kah Goh, Grace Gold, Christopher Christophi, Vijayaragavan Muralidharan. Serum carbohydrate antigen 19‐9 in pancreatic adenocarcinoma: a mini review for surgeons. ANZ Journal of Surgery 2017; 87(12) doi: 10.1111/ans.14131
19
Kavya Krishna, Tanios Bekaii-Saab. Biomarkers in Cancer. 2014;  doi: 10.1007/978-94-007-7744-6_17-1
20
Kohei Nishio, Kenjiro Kimura, Ryosuke Amano, Sadaaki Yamazoe, Go Ohrira, Bunzo Nakata, Kosei Hirakawa, Masaichi Ohira. Preoperative predictors for early recurrence of resectable pancreatic cancer. World Journal of Surgical Oncology 2017; 15(1) doi: 10.1186/s12957-016-1078-z
21
Ludmila Katherine Martin, Lai Wei, Elizabeth Trolli, Tanios Bekaii-Saab. Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Medical Oncology 2012; 29(5) doi: 10.1007/s12032-012-0278-9
22
Jason C. Maggi, Melissa E. Hogg, Amer H. Zureikat, Herbert J. Zeh. Update on the Management of Pancreatic Cancer: Determinants for Surgery and Widening the Therapeutic Window of Surgical Resection. Current Surgery Reports 2016; 4(7) doi: 10.1007/s40137-016-0146-1
23
Masaki Kuwatani, Hiroshi Kawakami, Yoshimasa Kubota, Kazumichi Kawakubo, Yoichi M. Ito, Shinji Togo, Takaaki Ikeda, Ken Kusama, Yuka Kobayashi, Teizo Murata, Naoya Sakamoto. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis. Pancreatology 2019; 19(4) doi: 10.1016/j.pan.2019.04.007
24
Lisheng Qian, Qiaobin Li, Kwaku Baryeh, Wanwei Qiu, Kun Li, Jing Zhang, Qingcai Yu, Dongqin Xu, Wenju Liu, Randall E. Brand, Xueji Zhang, Wei Chen, Guodong Liu. Biosensors for early diagnosis of pancreatic cancer: a review. Translational Research 2019; 213 doi: 10.1016/j.trsl.2019.08.002
25
Kavya Krishna, Tanios Bekaii-Saab. Biomarkers in Cancer. Biomarkers in Disease: Methods, Discoveries and Applications 2015;  doi: 10.1007/978-94-007-7681-4_17
26
Si Shi, Xianjun Yu. Selecting chemotherapy for pancreatic cancer: Far away or so close?. Seminars in Oncology 2019; 46(1) doi: 10.1053/j.seminoncol.2018.12.004
27
Holger Husi, Marco Fernandes, Richard Skipworth, Janice Miller, Andrew Cronshaw, Kenneth Fearon, James Ross. Identification of diagnostic upper gastrointestinal cancer tissue type‑specific urinary biomarkers. Biomedical Reports 2019;  doi: 10.3892/br.2019.1190
28
Marta Herreros-Villanueva, Lourdes Ruiz-Rebollo, Mario Montes, Mario Rodriguez-Lopez, María Francisco, Joaquín Cubiella, Eduardo Iyo, Emilio Garabitos, Emma Martínez Moneo, Maider Martos, Enrique de Madaria, Ibon Martínez-Arránz, Marta García-Cougil, Agueda Iglesias-Gómez, Luis Bujanda. CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Molecular Biology Reports 2020; 47(3) doi: 10.1007/s11033-020-05245-5
29
Giovanni Guarneri, Giulia Gasparini, Stefano Crippa, Valentina Andreasi, Massimo Falconi. Diagnostic strategy with a solid pancreatic mass. La Presse Médicale 2019; 48(3) doi: 10.1016/j.lpm.2019.02.026
30
Alexander C. Schulick, Hunter B. Moore, Salvador Rodriguez Franco, Jessie G. Jiang, Barish H. Edil, Richard D. Schulick, Trevor L. Nydam, Martin D. McCarter, Marco Del Chiaro, Ana Gleisner. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampullary and pancreatic adenocarcinoma. The American Journal of Surgery 2024; 238 doi: 10.1016/j.amjsurg.2024.115820
31
Ray Greek, Mark J Rice. Animal models and conserved processes. Theoretical Biology and Medical Modelling 2012; 9(1) doi: 10.1186/1742-4682-9-40
32
Soo-Youn Lee, Jong Kyun Lee, Sang-Mi Kim, Go Eun Bae. First large-scale prospective evaluation of serum S100A6 as a complementary biomarker for early pancreatic cancer detection. World Journal of Gastroenterology 2026; 32(21): 116581 doi: 10.3748/wjg.v32.i21.116581
33
Hidenori Takahashi, Hiroaki Ohigashi, Osamu Ishikawa, Hidetoshi Eguchi, Kunihito Gotoh, Terumasa Yamada, Akihiko Nakaizumi, Hiroyuki Uehara, Yasuhiko Tomita, Kinji Nishiyama, Masahiko Yano. Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival. Annals of Surgery 2010; 251(3) doi: 10.1097/SLA.0b013e3181cc90a3
34
Kun-Chun Chiang, Chun-Nan Yeh, Shir-Hwa Ueng, Jun-Te Hsu, Ta-Sen Yeh, Yi-Yin Jan, Tsann-Long Hwang, Miin-Fu Chen. Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. World Journal of Surgical Oncology 2012; 10(1) doi: 10.1186/1477-7819-10-77
35
John P. Hoffman. Status of Neoadjuvant Therapy for Resectable Pancreatic Cancer. Surgical Oncology Clinics of North America 2010; 19(2) doi: 10.1016/j.soc.2009.11.007
36
Renata Talar-Wojnarowska, Anita Gasiorowska, Marek Olakowski, Andrzej Lekstan, Pawel Lampe, Ewa Malecka-Panas. Clinical Value of Serum Neopterin, Tissue Polypeptide-Specific Antigen and CA19-9 Levels in Differential Diagnosis between Pancreatic Cancer and Chronic Pancreatitis. Pancreatology 2011; 10(6) doi: 10.1159/000320693
37
Jianli Su, Yunfeng Wang, Hua Shao, Xinting You, Shuying Li. Value of multi-detector computed tomography combined with serum tumor markers in diagnosis, preoperative, and prognostic evaluation of pancreatic cancer. World Journal of Surgical Oncology 2022; 20(1) doi: 10.1186/s12957-022-02785-x
38
Mina Waraya, Keishi Yamashita, Hiroyuki Katagiri, Kenichiro Ishii, Yoshihito Takahashi, Kazunori Furuta, Masahiko Watanabe. Preoperative Serum CA19-9 and Dissected Peripancreatic Tissue Margin as Determiners of Long-Term Survival in Pancreatic Cancer. Annals of Surgical Oncology 2009; 16(5) doi: 10.1245/s10434-009-0415-7
39
O. Turrini, C.M. Schmidt, J. Moreno, P. Parikh, J.M. Matos, M.G. House, N.J. Zyromski, A. Nakeeb, H.A. Pitt, K.D. Lillemoe. Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?. Journal of Gastrointestinal Surgery 2009; 13(10) doi: 10.1007/s11605-009-0916-5
40
Md Ariful Islam, Md Maniruzzaman, Khondokar Muhammad Abu Jalal, Md Tariq Hasan, Mohammod Ali. Relation of CA 19-9 Levels with Clinical and Radiological Features in Pancreatic Lesions. Kushtia Medical College Journal 2024; 8(2) doi: 10.70945/kumcj.v08.i02.133
41
Chi-Ying Yang, Ro-Ting Lin, Chi-Yi Chen, Chun-Chieh Yeh, Chao-Ming Tseng, Wen-Hsin Huang, Teng-Yu Lee, Chia-Shen Chu, Jaw-Town Lin. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma. Journal of the Formosan Medical Association 2022; 121(12) doi: 10.1016/j.jfma.2022.07.003
42
Hala O. El-Mesallamy, Nadia M. Hamdy, Ashraf S. Zaghloul, Alaliaa M. Sallam. Clinical Value of Circulating Lipocalins and Insulin-Like Growth Factor Axis in Pancreatic Cancer Diagnosis. Pancreas 2013; 42(1) doi: 10.1097/MPA.0b013e3182550d9d
43
Evelyn Waugh, Juan Glinka, Daniel Breadner, Rachel Liu, Ephraim Tang, Laura Allen, Stephen Welch, Ken Leslie, Anton Skaro. Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer. Annals of Hepato-Biliary-Pancreatic Surgery 2024; 28(2) doi: 10.14701/ahbps.23-107
44
Zhenhua Ma, Qingyong Ma, Zheng Wang. An evaluation of the diagnostic value of CA19-9 and CEA levels in patients with pancreatic cancer. Journal of Nanjing Medical University 2009; 23(3) doi: 10.1016/S1007-4376(09)60055-1
45
Gian Carlo Mattiucci, Alessio G. Morganti, Francesco Cellini, Milly Buwenge, Riccardo Casadei, Andrea Farioli, Sergio Alfieri, Alessandra Arcelli, Federica Bertini, Felipe A. Calvo, Silvia Cammelli, Lorenzo Fuccio, Lucia Giaccherini, Alessandra Guido, Joseph M. Herman, Gabriella Macchia, Bert W. Maidment, Robert C. Miller, Francesco Minni, William F. Regine, Michele Reni, Stefano Partelli, Massimo Falconi, Vincenzo Valentini. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Translational Oncology 2019; 12(1) doi: 10.1016/j.tranon.2018.08.017
46
Hadi M.H. Diab, Henry G. Smith, Kristian K. Jensen, Lars N. Jørgensen. The current role of blood-based biomarkers in surgical decision-making in patients with localised pancreatic cancer: A systematic review. European Journal of Cancer 2021; 154 doi: 10.1016/j.ejca.2021.05.033
47
Jesse Hinton, Richard Callan, Charlie Bodine, Wayne Glasgow, Steve Brower, Shi-Wen Jiang, Jinping Li. Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas. Expert Review of Molecular Diagnostics 2013; 13(5) doi: 10.1586/erm.13.38
48
Han Peng, Liyue Sun, Jie Zhao, Guofeng Cui. Electrochemical detection of circulating-free DNA methylation: A new indicator for early cancer screening. Talanta 2025; 292 doi: 10.1016/j.talanta.2025.127925
49
Naru Kondo, Yoshiaki Murakami, Kenichiro Uemura, Yasuo Hayashidani, Takeshi Sudo, Yasushi Hashimoto, Akira Nakashima, Ryutaro Sakabe, Norifumi Shigemoto, Yasushi Kato, Hiroki Ohge, Taijiro Sueda. Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer. Annals of Surgical Oncology 2010; 17(9) doi: 10.1245/s10434-010-1033-0
50
Maria Diab, Philip A. Philip. Current and Emerging Therapies in Pancreatic Cancer. 2018;  doi: 10.1007/978-3-319-58256-6_6
51
Raffaele Pezzilli. Endoscopic Ultrasound Management of Pancreatic Lesions. 2021;  doi: 10.1007/978-3-030-71937-1_1
52
Roopali Roy, Christine M. Coticchia, Jiang Yang, Marsha A. Moses. Biomarkers. 2010;  doi: 10.1002/9780470918562.ch14
53
Tianlei Wang, Xinrui Bao, Fang Yang, Shenbin Pan, Ke Xu, Tao Ren. Plasma COL10A1 Level, a Potential Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. OncoTargets and Therapy 2024;  doi: 10.2147/OTT.S474540
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.